New shareholder may be 'new blood' needed for Cordlife's anaemic trajectory
LET'S face it - Cordlife Group is long overdue for a reset. The mainboard-listed cord blood banking and family diagnostic services provider has done nothing remarkable in recent years - except to survive.
Its one big hurrah was six years ago, when it sold its shares and convertible notes in China Cord Blood Corp - mainland China's first and largest cord blood group - and pocketed handsome gains, sharing the sweetness with shareholders in the form of a special dividend of S$0.13 per share.
The company's much-trumpeted goal to expand in South-east Asia has come to little. And the controversial exit of its long-serving chief executive Jeremy…
SEE ALSO
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Axiata, Sinar Mas move closer to US$3.5 billion telco merger
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
VinFast chief plans to invest US$1 billion more from his fortune in EV maker
XPeng CEO says its software, AI upgrades to enter ‘super fast cycle’
Asia: Markets mixed as global rally stalls, eyes on yen